Seòmar agus comataidhean

Following the publication of the Framework for supporting people through Recovery and Rehabilitation during and after the COVID-19 , the rehabilitation programme has undertaken a significant scoping exercise through a self-assessment tool to understand the current status of rehabilitation services in Scotland, from the perspective of the staff working in them.

The report on the findings ( Rehabilitation Framework Self-Assessment Tool: Analysis of Survey Responses ) was published on 9th December 2021.

The findings from the self-assessment tool, along with demand and capacity data and guidance from the National Advisory Board on Rehabilitation, will inform the development of a national programme of improvement work to deliver a ‘Once for Scotland’ rehabilitation pathway that will ensure everyone who requires rehabilitation will be able to access it.

We will continue to work with NHS Boards, Health and Social Care Partnerships and the third sector to deliver this.

Details (including individual project funding allocations) of the 9 research projects funded through the Chief Scientist Office (CSO) long-term effects of COVID-19 infection call are available from the CSO website Long Covid Call – Chief Scientist Office (scot.nhs.uk) .

I refer the member to the answer to question S6W-04072 on 22 November 2021. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers .

The Tobacco and Primary Medical Services (Scotland) Act 2010 prohibits the display of tobacco related products inside retailer premises. No advertising of branded tobacco products is permitted either inside or outside a premise but stores are allowed to have generic, unbranded signs stating they sell tobacco on in-store gantries, and outside of buildings, however the latter is actively discouraged.

Any concerns around the compliance of a particular premises with Scottish law should be directed to the local authority. The Scottish Government provide funding of £1.34 million annually to councils for the enforcement of the legislation around the sale and purchase of tobacco and NVP’s. Local authority trading standards services treat the enforcement of legislation as a high priority issue.

We know that it will take time and a series of targeted actions to build back capacity and redesign patient pathways to bring treatment times back within targets for orthopaedic patients.

As part of the NHS Recovery Plan , which is backed by an overall investment of £1 billion, the Scottish Government is investing over £400 million to deliver 10 National Treatment Centres (NTCs) which will create protected elective capacity for an additional 40,000 surgeries and procedures across 12 specialties per year. The first of these opened at the Golden Jubilee in November 2020 and next three NTCs are due to open in NHS Fife, NHS Forth Valley and NHS Highland in 2022. These centres will be crucial to increasing orthopaedic capacity, which will in turn reduce the length of time patients are waiting for treatment.

Services are also embracing new ways of working, including virtual clinics and Active Clinical Referral Triage, which will support shorter time to diagnosis and treatment and continue to ensure patients receive the appropriate advice and support.

Funding provided by the Scottish Government (Chief Scientist Office) for research falls into three broad areas of activity, i.e. research studies, capacity building and supporting infrastructure.

The specific amounts provided by condition are set out below although it should be noted that research studies (funded by non-commercial and third sector organisations) would also have benefited from the provision of service support costs and other generic resources which are not routinely recorded by condition.

Research Grants

The Chief Scientist Office supports response mode grant committees and a small catalytic grants scheme (2016-19). The committees which comprise independent experts as well as public representatives consider applications across broad research remits to address health and care challenges in Scotland. Applications are subject to independent expert peer-review with funding recommendations made by the committees. It should be noted that (1) funding rounds were significantly impacted in 2020 due to the COVID-19 pandemic which saw a significant research response and (2) for 2021 to date only one of the two funding rounds has been completed.

We have not made a direct assessment of the impact of the Covid-19 pandemic on the detection of atrial fibrillation. However, we regularly assess statistics on Covid-19’s impact on cardiovascular services more widely to inform our work.

Public Health Scotland Statistics on COVID-19’s impact on the health care system including cardiovascular procedures can be found at:

https://scotland.shinyapps.io/phs-covid-wider-impact/

To address the wider impacts of the pandemic our NHS Recovery Plan, backed by over £1bn of investment, sets out our plans for health and care over the next five years. Through the plan we will take forward our aim of increasing NHS capacity by at least 10% as quickly as possible to address the backlog of care and meet the ongoing healthcare needs for people across the country.

The requested information on how many people were diagnosed with multiple sclerosis (MS), broken down by NHS board is not held centrally.

The Scottish Multiple Sclerosis Register provides information on new diagnoses of MS. The latest publication of the register shows 450 new patients with a confirmed diagnosis of MS were added to the MS Register in 2020.

I can confirm that the project remains on budget. There is no change to the estimated total project cost of £49.5m at Q4 2018 prices, of which the construction contract value is £18m, as reported in the Infrastructure Investment Plan updates.

Construction cost updates for the project are published on the Scottish Government website every 6 months via the Major Capital Projects update.

Prioritisation within the Scottish Government’s COVID-19 vaccination programme is based upon the clinical risk of developing severe disease with COVID-19. The Joint Committee on Vaccination and Immunisation (JCVI) advises on clinical prioritisation for vaccination. Priority groups 1-9 incorporate the highest clinical risk groups and each group cohort is invited to receive vaccination accordingly.

As per guidance outlined within the Green Book, Chapter 14a, children and young people aged 12-15 years with poorly controlled asthma that requires continuous or repeated use of systemic steroids or with previous exacerbations requiring hospital admission, are included as a high risk group within chronic respiratory disease.

For full details please see p19-23: COVID-19: the green book, chapter 14a - GOV.UK (www.gov.uk) .